Impact of Type 2 Diabetes on Five-year Clinical Outcomes Following Successful Percutaneous Coronary Intervention on Chronic Total Occlusions: a Propensity Matched Cohort Analysis

Peizhi Wang
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Deshan Yuan
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Sida Jia
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Pei Zhu
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Ce Zhang
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Yue Liu
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Tianyu Li
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Lin Jiang
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Ying Song
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Jingjing Xu
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Xiaofang Tang
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Xueyan Zhao
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Bo Xu
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Yuejin Yang
Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital

Jinqing Yuan (dr_jinqingyuan@sina.com)
Original investigation

Keywords: Chronic total occlusion, Percutaneous coronary intervention, Diabetes mellitus, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-378689/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Despite substantial improvement in chronic total occlusions (CTO) revascularization technique, the long-term clinical outcomes in diabetic patients with revascularized CTO remain controversial. Our study aimed to investigate the five-year cardiovascular survival for patients with or without type 2 diabetes mellitus (DM) who underwent successful percutaneous coronary intervention (PCI) for CTO.

**Methods:** Data of the current analysis derived from a large single-center, prospective and observational cohort study, including 10,724 patients who underwent PCI in 2013 at Fuwai Hospital. Baseline, angiographic and follow-up data were collected. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), which consisted of death, recurrent myocardial infarction (MI), stroke and target vessel revascularization (TVR). The secondary endpoint was all-cause mortality. Cox regression analysis and propensity-score matching was performed to balance the baseline confounders.

**Results:** A total of 719 consecutive patients with ≥ 1 successful CTO-PCI were stratified into diabetic (n=316, 43.9%) and non-diabetic (n=403, 56.1%) group. During a median follow-up of 5 years, the risk of MACCE (adjusted hazard ratio [HR] 1.47, 95% confidence interval [CI] 1.08-2.00, P = 0.013) was significantly higher in the diabetic group than in the non-diabetic group, whereas the adjusted risk of all-cause mortality (HR 2.37, 95% CI 0.94-5.98, P = 0.068) was similar. In the propensity score matched population, there were no significant differences in the risk of MACCE (HR 1.27, 95% CI 0.92-1.75, P = 0.068) and all-cause mortality (HR 2.56, 95% CI 0.91-7.24, P = 0.076) between groups. Subgroup analysis revealed a consistent effect on five-year MACCE across various subgroups.

**Conclusions:** In patients who received successful CTO-PCI, non-diabetic patients were related to better long-term survival benefit in terms of MACCE. Further randomized studies are warranted to confirm these findings.

Introduction

Chronic total occlusion (CTO) occurs in approximately 15–25% of patients with coronary artery disease (CAD) undergoing diagnostic coronary angiography[1, 2]. Due to the development of interventional devices and dedicated techniques, percutaneous coronary intervention (PCI) for CTO has achieved high technical success rates with a low risk for procedural complications, especially in tertiary medical centers. Current guidelines have regarded revascularization for CTO as the IIa B recommendation[3]. Considerable evidence suggest that successful CTO-PCI is related to a better improvement of symptoms, quality of life, and ventricular function compared to optimal medical treatment alone and unsuccessful CTO-PCI[4–6], whereas the benefit in terms of improving patient survival was not significant[7, 8]. The beneficial effect of CTO-PCI on long-term prognosis is still controversial[2, 9], especially for the special group of people with diabetes.
Type 2 Diabetes mellitus (DM) is a well-established CAD risk equivalent and is associated with a greater atherosclerotic burden, such as multivessel disease, heavily calcified coronary lesions, diffuse and small vessel CAD\[10, 11\]. Previous studies have reported that patients with DM have an elevated incidence of CTO (approximately 30–40%)\[12, 13\]. In addition, CTO patients with DM are related to longer and more technically challenging occluded lesions, with lower success rates compared with that in non-DM\[14\]. Besides, non-DM patients were more likely to fare better after CTO-PCI for up to 3 years compared to their DM counterparts\[15\]. However, to the best of our knowledge, no previous study has focused on longer term impact of successful recanalisation for CTO lesions in patients with versus without DM. Therefore, we conducted a prospective, observational and real-world study to investigate five-year clinical outcomes in type 2 diabetic and non-diabetic patients after successful CTO-PCI.

**Method**

**Study population**

A total of 10,724 consecutive patients with CAD who underwent PCI were enrolled between January 2013 and December 2013 in Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China. Notably, we included 1010 (9.42%) patients with at least 1 CTO lesion. CTO lesions were defined as complete obstruction of a native coronary artery for longer than 3 months with thrombolysis in myocardial infarction (TIMI) flow grade of 0\[16\]. Patients who received recanalisation treatment for CTO depended on contemporary practice guidelines, judgment from our team’s experienced cardiologists and their own preference\[17\]. Exclusion criteria included the following: (1) patients who underwent unsuccessful CTO-PCI (n=267); (2) patients lacking both hemoglobin A\(_1c\) (HbA\(_1c\)) and fasting plasma glucose (FPG) data (n=9); (3) patients who were diagnosed as acute STEMI within 72h before admission (n=15). Thus, the remaining 316 (43.9%) patients with type 2 DM and 403 (56.1%) patients without DM were enrolled for the final analysis (Figure 1). DM was defined as a FPG of at least 7.0 mmol/L, or glycated HA\(_1c\) greater than 6.5% or known diabetes, based on previous medical records of the patients and data of the therapeutic status based on the glucose-lowering therapy\[18\]. Left ventricular ejection fraction (LVEF) was measured from two-dimensional echocardiography according to modified Simpson’s rule. Estimated glomerular filtration rate (eGFR) was calculated by the modified diet in renal disease equation for Chinese\[19\]. Data of demographic, clinical and angiographic features were collected from the database and medical records retrospectively, whereas clinical endpoints during follow-up were identified prospectively. The study complied with the principles of the Declaration of Helsinki and was approved by the Institutional Ethics Committee at Fu Wai Hospital. All eligible participants gave written informed consent.

**PCI procedures**

Coronary interventions were performed according to current standard guidelines at the discretion of the operating physician\[17\]. Before catheterization, unless on chronic P2Y12 inhibitor therapy for > 6 days, selected PCI patients received oral administration of aspirin 300 mg and clopidogrel (loading dose 300
mg) or ticagrelor (loading dose 180 mg) at least 24h. Patients presenting as acute coronary syndrome (ACS) scheduled for PCI received the same dose of aspirin and ticagrelor or clopidogrel (loading dose 300 or 600 mg) as soon as possible. Thereafter, unfractionated heparin (100 U/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the operator's judgment. CTO-PCI was done using bilateral injections, specialized hydrophilic wires, microcatheters and retrograde approach, when available. If both antegrade and retrograde approaches failed, intravascular ultrasound (IVUS) guided wire re-entry technique would be attempted. Standard dual-antiplatelet medication was maintained for at least 12 months after PCI. The PCI procedure was considered successful if residual stenosis < 30% with TIMI flow grade 3 at the end of the procedure was obtained according to visual estimation of the angiograms.

Endpoints and follow-up

The primary clinical outcome was the occurrence of 5-year major adverse cardiac and cerebrovascular events (MACCE) during follow-up, a composite endpoint of death, recurrent myocardial infarction (MI), stroke and target vessel revascularization (TVR). The secondary endpoint was all-cause mortality. Death that could not be attributed to a noncardiac etiology was considered cardiac death. MI was defined by the Third Universal Definition[20]. TVR was defined as revascularization for a new lesion on the target vessel either by PCI or by surgery[21].Patients were evaluated at 1, 6 and 12 months postoperatively and annually thereafter for up to 5 years. Clinical follow-up was performed through examination of hospital records, telephone follow-up and outpatient clinical visit by research coordinators.

Statistical analysis

Categorical variables were compared with Chi-square test or Fisher's exact test, where applicable, and data were presented as frequencies and percentages. Continuous variables were tested using Student's t-test and were summarized as the mean ± standard deviation. The cumulative incidence of clinical outcomes was calculated by Kaplan–Meier analysis and compared using log-rank test. Covariates that were significant on univariate analysis (P < 0.10) or clinically relevant were included in multivariate models. Cox regression was used to compare adjusted hazard ratios based on age, eGFR, LVEF, prior stroke, prior PCI, prior MI, left anterior descending coronary artery (LAD) involvement and peripheral vascular disease (PVD) (Details available in Additional file, Table S1). Additionally, propensity score matching (PSM) analysis was constructed to adjust for any potential confounder in baseline characteristics between the two groups based on multivariable logistic regression model. The nearest neighbor matching algorithm was used for PSM via a 1:1 matching protocol. Exploratory subgroup analysis was carried out to assess the effect of glycemic status (DM and Non-DM) on MACCE in specific patient subsets using the same multivariable model. Cox regression analysis was also conducted to compare the DM group with non-DM group in the risk of MACCE and all-cause mortality during 2 years of follow-up. Two-tailed P value of less than 0.05 was considered as statistically significance. The SPSS Version 26.0 (SPSS Inc., Chicago, Illinois, USA) was used for all statistical computations.
Results

Baseline patient characteristics

The prevalence of CTO was 9.42% in the total population. Success rate of CTO-PCI was 73.6%. Among a total of 719 selected patients with at least 1 successful CTO-PCI at least in our prospective and observational cohort, 316 (43.9%) patients had DM and 69 (21.8%) were dependent on insulin (Fig. 1). The baseline demographic and treatment characteristics of the patients with and without DM are shown in Table 1. Notably, compared with non-diabetic patients, those in the DM group were older, had more females in gender distribution and exhibited a higher percentage of current smoking, hypertension, hyperlipidemia, lower LVEF, lower eGFR, prior PCI, prior MI and prior coronary artery bypass grafting (CABG). Previous stroke and higher level of low-density lipoprotein cholesterol were more common in the non-diabetic group. We did not observe a significant difference in the choice of baseline medication. Angiographic and procedural characteristics of the patients are shown in Table 2. Patients in the diabetes group more often had LAD involvement, one CTO lesion, severe calcification, angulation > 45° and multivessel disease. However, SYNTAX score and J-CTO score between the two groups were similar. After performing propensity score matching for the enrolled patients, 289 matched pairs of patients were created and we did not find considerable differences in the baseline clinical and lesion characteristics between the two matched groups (Table 1,2).
Table 1
Baseline clinical characteristics in the diabetes and the non-diabetes groups

| Variables                          | Total population (n = 719) | Propensity-matched patients (n = 578) |
|-----------------------------------|---------------------------|--------------------------------------|
|                                   | Diabetes (n = 316)        | Non-diabetes (n = 403)               |
|                                   | P value                   | Propensity-matched patients           | P value |
|                                   |                           | Diabetes (n = 289)                   | Non-diabetes (n = 289) |
| Age (years)                       | 57.8 ± 10.2               | 57.4 ± 10.2                          | 0.141   | 56.7 ± 10.2 | 56.6 ± 10.2 | 0.347 |
| Male                              | 261 (82.6)                | 342 (84.9)                           | 0.412   | 240 (83.0) | 243 (84.1) | 0.736 |
| Current smoking                   | 201 (63.6)                | 248 (61.5)                           | 0.570   | 184 (63.7) | 185 (64.0) | 0.931 |
| Hypertension                      | 209 (66.1)                | 245 (60.8)                           | 0.140   | 186 (64.4) | 180 (62.3) | 0.605 |
| Hyperlipidemia                    | 227 (71.8)                | 278 (69.0)                           | 0.406   | 208 (72.0) | 199 (68.9) | 0.412 |
| LVEF (%), at baseline             | 60.2 ± 8.6                | 62.6 ± 6.7                           | 0.000   | 61.45 ± 7.2 | 62.5 ± 6.6 | 0.066 |
| eGFR (ml/min)                     | 91.3 ± 16.6               | 93.1 ± 13.7                          | 0.107   | 92.15 ± 16.2 | 93.35 ± 13.7 | 0.340 |
| LDL-C (mmol/L)                    | 2.45 ± 0.9                | 2.51 ± 1.0                           | 0.399   | 2.47 ± 0.9 | 2.49 ± 1.1 | 0.778 |
| Prior stroke                      | 3 (0.9)                   | 6 (1.5)                              | 0.738   | 3 (1.0)    | 2 (0.7)    | 1.000 |
| Prior PCI                         | 76 (24.1)                 | 89 (22.1)                            | 0.534   | 65 (22.5)  | 62 (21.5)  | 0.763 |
| Prior MI                          | 97 (30.7)                 | 115 (28.5)                           | 0.528   | 81 (28.0)  | 79 (27.3) | 0.853 |
| Prior CABG                        | 25 (7.9)                  | 28 (6.9)                             | 0.624   | 21 (7.3)   | 21 (7.3)  | 1.000 |
| Familial history of CAD           | 71 (22.5)                 | 93 (23.1)                            | 0.847   | 65 (22.5)  | 72 (24.9) | 0.494 |
| COPD                              | 7 (2.2)                   | 12 (3.0)                             | 0.527   | 7 (2.4)    | 7 (2.4)   | 1.000 |
| PVD                               | 8 (2.5)                   | 10 (2.5)                             | 0.966   | 3 (1.0)    | 7 (2.4)   | 0.202 |
| Insulin-dependent DM              | 69 (21.8)                 | -                                    | -       | 60 (20.8)  | -         | -     |
| **Baseline medication**           |                           |                                      |         |            |            |       |
| Aspirin                           | 313 (99.1)                | 400 (99.3)                           | 1.000   | 286 (99.0) | 287 (99.3) | 1.000 |
| Clopidogrel                       | 315 (99.7)                | 403 (100.0)                          | 0.439   | 289 (100.0) | 289 (100.0) | 1.000 |
| Statin                            | 305 (96.5)                | 390 (96.8)                           | 0.850   | 279 (96.5) | 279 (96.5) | 1.000 |
| Variables | Total population (n = 719) |  | Propensity-matched patients (n = 578) |  |
|-----------|---------------------------|  |--------------------------------------|  |
|           | Diabetes (n = 316) | Non-diabetes (n = 403) | Diabetes (n = 289) | Non-diabetes (n = 289) |
| β blocker | 300 (94.9) | 369 (91.6) | 0.078 | 274 (94.8) | 269 (93.1) | 0.383 |
| CCB       | 144 (45.6) | 188 (46.7) | 0.773 | 137 (47.4) | 131 (45.3) | 0.617 |

Values are presented as mean ± standard deviation or number (%).

LVEF: left ventricular ejection fraction; eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; PCI: percutaneous coronary intervention; MI: myocardial infarction; CABG: coronary artery bypass grafting; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; PVD: peripheral vessel disease; DM: diabetes mellitus; CCB: calcium channel blocker.
### Table 2
Lesion and treatment characteristics in the diabetes and the non-diabetes groups

| Variables                                      | Total population (n = 719) |  | P value | Propensity-matched patients (n = 578) |  | P value |
|-----------------------------------------------|---------------------------|---|---------|--------------------------------------|---|---------|
|                                              | Diabetes (n = 316) | Non-diabetes (n = 403) |         | Diabetes (n = 289) | Non-diabetes (n = 289) |         |
| **Characteristics of CTO lesion**             |                          |                          |         |                                      |                          |         |
| One CTO lesion                                | 244 (77.2)               | 301 (74.7)               | 0.433   | 220 (76.1)                           | 216 (74.7)               | 0.699   |
| Two CTO lesions                               | 41 (13.0)                | 68 (16.9)                | 0.148   | 39 (13.5)                            | 48 (16.6)                | 0.295   |
| **Location of CTO lesions**                   |                          |                          |         |                                      |                          |         |
| LAD                                           | 131 (41.5)               | 163 (40.4)               | 0.785   | 116 (40.1)                           | 118 (40.8)               | 0.865   |
| LCX                                           | 57 (18.0)                | 57 (14.1)                | 0.156   | 54 (18.7)                            | 41 (14.2)                | 0.145   |
| RCA                                           | 132 (41.8)               | 186 (46.2)               | 0.240   | 123 (42.6)                           | 133 (46.0)               | 0.402   |
| Multivessel disease                           | 267 (84.5)               | 331 (82.1)               | 0.401   | 245 (84.8)                           | 236 (81.7)               | 0.316   |
| Proximal or mid                               | 240 (75.9)               | 324 (80.4)               | 0.150   | 219 (75.8)                           | 233 (80.6)               | 0.158   |
| Severe Calcification                          | 20 (6.3)                 | 23 (5.7)                 | 0.727   | 19 (6.6)                             | 22 (7.6)                 | 0.627   |
| Length ≥ 20mm                                 | 283 (89.6)               | 373 (92.6)               | 0.158   | 258 (89.3)                           | 268 (92.7)               | 0.146   |
| Angulation > 45°                              | 59 (18.7)                | 61 (15.1)                | 0.207   | 59 (20.4)                            | 69 (23.9)                | 0.316   |
| Vessel diameter (mm)                          | 2.97 ± 0.5               | 2.99 ± 0.5               | 0.397   | 2.97 ± 0.5                           | 2.99 ± 0.5               | 0.621   |
| SYNTAX score                                  | 17.30 ± 9.0              | 17.30 ± 8.6              | 0.997   | 17.26 ± 9.1                          | 17.17 ± 9.0              | 0.909   |
| J-CTO score                                   | 1.17 ± 0.6               | 1.16 ± 0.5               | 0.877   | 1.16 ± 0.59                          | 1.24 ± 0.57              | 0.100   |
| **Treatment characteristics**                 |                          |                          |         |                                      |                          |         |
| Number of stents for CTO-PCI                  |                          |                          |         |                                      |                          |         |
| 1                                             | 48 (15.2)                | 75 (18.6)                | 0.227   | 43 (14.9)                            | 52 (18.0)                | 0.312   |
| Variables                     | Total population (n = 719) | Propensity-matched patients (n = 578) |
|-------------------------------|---------------------------|--------------------------------------|
|                               | P value                   | P value                              |
|                               | Diabetes (n = 316)        | Non-diabetes (n = 403)               | Diabetes (n = 289) | Non-diabetes (n = 289) |
| 2                             | 110 (34.9)                | 144 (35.7)                           | 100 (34.6)        | 100 (34.6)             |
|                               | 0.821                     | 1.000                                |
| ≥ 3                           | 109 (34.5)                | 140 (34.7)                           | 101 (34.9)        | 103 (35.6)             |
|                               | 0.945                     | 0.862                                |
| Stent length (mm)             | 53.42 ± 26.4              | 54.09 ± 25.5                         | 52.98 ± 26.3      | 55.44 ± 26.4           |
|                               | 0.742                     | 0.283                                |
| IVUS use                      | 38 (12.0)                 | 52 (12.9)                            | 35 (12.1)         | 38 (13.1)              |
|                               | 0.724                     | 0.707                                |

Values are presented as mean ± standard deviation or number (%).

CTO: chronic total occlusion; LAD: left ascending coronary artery; LCX: left circumflex coronary artery; RCA: right coronary artery; J-CTO: Japanese-chronic total occlusion; PCI: percutaneous coronary intervention; IVUS: intravenous ultrasound.

**Follow-up outcomes**

Over a median follow-up time was 5 (interquartile range: 2.5–5.1) years, 23 (3.2%) deaths and 175 (24.3%) MACCE occurred. DM group had a higher incidence of MACCE (diabetes vs. non-diabetes: 28.5% vs. 21.1%, unadjusted hazard ratio [HR] 1.40, 95% confidence interval [CI] 1.04–1.88, P = 0.028) and all-cause mortality (diabetes vs. non-diabetes: 5.1% vs. 1.7%, adjusted HR 2.97, 95% CI 1.22–7.23, P = 0.016). Kaplan-Meier curve analysis showed that similar results (Fig. 2). Through multivariate analysis, we found that the MACCE risk was significantly higher in the diabetic patients compared to the non-diabetic patients (adjusted HR 1.47, 95% CI 1.08–2.00, P = 0.013). However, the occurrence of all-cause mortality (adjusted HR 2.37, 95% CI 0.94–5.98, P = 0.068) was not significantly different between the diabetic and non-diabetic groups (Table 3).
Table 3
Risk of various clinical outcomes up to 5 years in all patients

| Outcomes               | Incidence of event at 5 years [n (%)] | Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
|------------------------|---------------------------------------|-------------------|---------|----------------------|---------|
|                        | Diabetes (n = 316)                     |                   |         |                      |         |
|                        | Non-diabetes (n = 403)                |                   |         |                      |         |
| All-cause mortality    | 16 (5.1)                              | 2.97 (1.22–7.23)  | 0.016   | 2.37 (0.94–5.98)     | 0.068   |
| Cardiac death          | 7 (2.2)                               | 2.26 (0.66–7.73)  | 0.192   | 1.17 (0.30–4.60)     | 0.822   |
| MI                     | 23 (7.3)                              | 0.93 (0.54–1.59)  | 0.790   | 0.91 (0.52–1.59)     | 0.744   |
| Stroke                 | 11 (3.5)                              | 1.30 (0.56–2.99)  | 0.541   | 1.00 (0.43–2.35)     | 1.000   |
| TVR                    | 64 (20.3)                             | 1.25 (0.89–1.76)  | 0.204   | 1.28 (0.90–1.81)     | 0.169   |
| MACCE                  | 90 (28.5)                             | 1.40 (1.04–1.88)  | 0.028   | 1.47 (1.08–2.00)     | 0.013   |

MI: myocardial infarction; TVR: target-vessel revascularization; MACCE: major adverse cardiac and cerebrovascular events.

In propensity score-matched patients, Cox regression analyses showed no significant differences between the two matched groups with regards to the prevalence of MACCE (diabetes vs. non-diabetes: 29.1% vs. 23.2%, unadjusted HR 1.27, 95% CI 0.92–1.76, P = 0.141) and all-cause mortality (diabetes vs. non-diabetes: 4.5% vs. 1.7%, unadjusted HR 2.66, 95% CI 0.95–7.47, P = 0.063). The results of univariable and multivariable analyses showed that the risk for the primary and secondary clinical outcomes was similar between the two matched group after PSM (Table 4).
Table 4
Risk of various clinical outcomes up to 5 years in propensity-matched patients

| Outcomes                  | Incidence of event at 5 years [n (%)] | Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
|---------------------------|---------------------------------------|-------------------|---------|----------------------|---------|
|                           | Diabetes (n = 316)                    |                   |         |                      |         |
|                           | Non-diabetes (n = 403)                |                   |         |                      |         |
| All-cause mortality       | 13 (4.5)                              | 2.66 (0.95–7.47)  | 0.063   | 2.56 (0.91–7.24)     | 0.076   |
| Cardiac death            | 4 (1.4)                               | 1.36 (0.30–6.06)  | 0.690   | 1.18 (0.25–5.50)     | 0.835   |
| MI                        | 22 (7.6)                              | 0.93 (0.52–1.66)  | 0.807   | 0.94 (0.53–1.68)     | 0.835   |
| Stroke                    | 11 (3.8)                              | 1.88 (0.69–5.07)  | 0.216   | 1.00 (0.39–2.60)     | 1.000   |
| TVR                       | 61 (21.1)                             | 1.13 (0.79–1.64)  | 0.502   | 1.13 (0.78–1.64)     | 0.509   |
| MACCE                     | 84 (29.1)                             | 1.27 (0.92–1.76)  | 0.141   | 1.27 (0.92–1.75)     | 0.155   |

Mi: myocardial infarction; TVR: target-vessel revascularization; MACCE: major adverse cardiac and cerebrovascular events.

Additionally, after adjustment of underlying confounding factors using the same method of previous Cox regression analysis, we did not find significant difference between the two groups in the risk of MACCE (adjusted HR 1.37, 95% CI 0.93–2.03, P = 0.106) and all-cause mortality (adjusted HR 1.14, 95% CI 0.28–4.63, P = 0.849) at 2 years (Details available in Additional file, Table S2).

Post-hoc subgroup analysis showed no significant interactions following MACCE between those covariates (age, sex, hypertension, hyperlipidemia, LVEF and SYNTAX score, all P for interaction > 0.05) and patients’ glycemic status (Fig. 3).

Discussion

We assessed the 5-year cardiovascular survival of successful CTO-PCI patients with or without DM in a large-scale, prospective and real-world cohort population. Notably, we confirmed the following: (1) Diabetic patients with successful recanalization for CTO lesions are highly prone to lower LVEF, compared with non-diabetic patients. (2) Non-diabetic patients were related to better long-term survival benefit in terms of MACCE for the treatment of successful CTO-PCI.
With substantial and significant improvement in interventional devices and techniques, CTO-PCI has emerged as an effective revascularization strategy with high success rates for diabetic patients. Moreover, it is well-established that DM represents an important risk equivalent of CTO and an independent factor for increased MACE after CTO-PCI[22, 23]. Sanguineti et al. reported that DM was a significant predictor of cardiac mortality in CTO patients[24]. Additionally, Yan et al. found that both successful CTO-PCI and CTO-CABG of right coronary artery in diabetic patients showed significant reduction of all-cause death (HR 0.445, 95% CI 0.278–0.714) during long-term follow-up[25]. Recently, Guo et al. also reported that in DM group, successful CTO-PCI reduced MACE risk (HR 0.61, 95% CI 0.42–0.87, P = 0.005) compared to optimal medical therapy alone[26]. Likewise, Tsai et al. also found that DM was associated with poor prognosis in patients with CTO lesions compared with non-DM[15]. Moreover, this study also showed that successful CTO-PCI was independently associated with reduced risks of all-cause death and adverse cardiovascular events only in DM population, but not in non-DM patients, which was consistent with the finding of Guo and co-workers[26]. These evidences highlighted the unfavorable role of DM in CTO patients and the importance of complete recanalization of CTO patients with DM. Contrary to the results of previous findings, subgroup analysis of the randomized COURAGE trial demonstrated that there was no obvious difference in the incidence of adverse events between the medical therapy group and the PCI group in DM patients with stable coronary disease[27]. This difference may be explained by the high rate (approximately 30%) of crossover from medication to revascularization during the follow-up period, which may underestimate the actual effect of successful CTO-PCI.

Considerable evidence has demonstrated that the existence of DM has a detrimental effect on glucose and lipid metabolism, endothelial function and angiogenesis, leading to premature development and progression of coronary artery atherosclerosis, inadequate collateral development and harmful clinical outcomes[28–30]. Previous studies have showed that well-established collateral circulation after CTO is crucial to supply the downstream perfusion area, alleviate myocardial damage, reduce infarct size and eventually improve LVEF[31, 32]. Our study found that DM patients with successful CTO-PCI were more likely to have lower LVEF, which may be related to poor coronary collateral circulation. However, recently, Yang et al. reported that after successful recanalization of CTO, there was no significant distinction between diabetic and non-diabetic effects of coronary collaterals on MACCE and repeat revascularization during a median follow-up of 13.5 months[33]. Yang and co-workers speculated that well-developed coronary collaterals may not adequately substitute normal blood supply and thus good collateral circulation is insufficient.

Recently, with regard to the long-term clinical outcomes of successful CTO-PCI in patients with versus without DM, a meta-analysis by Zhu et al. which included 9847 patients after successful CTO-PCI (4238 diabetic patients and 5069 non-diabetic patients) revealed that the prevalence of MACEs (RR 1.26, 95% CI 1.02–1.56, P = 0.03) was significantly higher, compared with patients without DM[34]. Likewise, consistent with Guo and co-workers[26], our study also reported that the rates of MACCE after successful CTO-PCI were higher in diabetic patients than in non-diabetic patients. In contrast, Ruiz Garcia et al. reported that in patients who underwent successful revascularization of CTO comparable rate of MACE was observed between the diabetic and non-diabetic patients in the drug-eluting stent era[35]. Although
this was a prospective randomized clinical study, the atypical definition of CTO (occlusion longer than 2 weeks), the small sample size of its enrolled patients (75 diabetic and 132 non-diabetic patients) and the modest follow-up period of 1 year restricted the accuracy of the results. In our study, we also found that the prevalence of 2-year (shorter term) clinical outcomes was comparable between the diabetic patients and non-diabetic patients, which was consistent with the findings of Ruiz Garcia and co-workers. Thus, it is necessary to evaluate longer term prognosis for diabetic patients undergoing successful CTO-PCI.

To date, there is a paucity of data on the benefit of successful PCI for CTOs in diabetic and non-diabetic patients on long-term survival. Our findings can be explained by the following mechanisms. First, patients in DM group were more likely to have complex clinical characteristics, like lower LVEF, which had a detrimental effect on cardiac function[10, 14]. Second, DM, as a greater risk factor for adverse cardiovascular outcomes, alters glucose and lipid metabolism and influences vascular endothelial function and angiogenesis[28, 29, 33]. Third, poor collateral circulation and microcirculation in diabetic patients may also partially account for the worse long-term prognosis, compared with non-diabetic patients[31, 33, 36].

Our study had some inevitable limitations. First, it was a single-center, prospective and observational study. Although we performed propensity score matching to reduce potential selection bias and minimize the confounding factors, unadjusted confounders still existed. Second, our real-world cohort comprised of CAD patients, who had been consecutively enrolled in our study and underwent PCI. This was not a specialized CTO cohort, so we are short in sample size of CTO-PCI patients. Third, there was a lack of specific information in our database, such as coronary collateral scoring. Fourth, our center was a tertiary medical hospital which performed high volume of CTO-PCI and had many experienced cardiologists. Generalizability might be limited in less experienced center with lower number of CTO-PCI cases.

Conclusions

The present study suggests that diabetic patients with successful CTO-PCI encountered more long-term adverse clinical outcomes, based on their complex lesions and co-morbidities. After a successful CTO-PCI, non-diabetic patients were associated with better long-term survival benefit in terms of MACCE. These findings may provide clinical insight into treatment option for unselected patients with diabetes. Further randomized controlled trials with longer term follow-up are required to validate our results.

Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the Fuwai hospital’s Research Ethics Committee. The Institutional Review Board approved the study protocol and all of the participants provided written informed consent.

Consent for publication
The manuscript was approved by all authors for publication.

**Availability of data and materials**

Due to ethical restrictions related to the consent given by subjects at the time of study commencement, our datasets are available from the corresponding author upon reasonable request after permission of the Institutional Review Board of State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases.

**Competing interests**

The authors declare that they have no conflict of interest.

**Funding**

This research was supported by grants from Ministry of Science and Technology of the People’s Republic of China (2016YFC1301300, 2016YFC1301301) and National Natural Science Foundation of China (No. 81770365).

**Authors’ contributions**

WPZ, YDS, JSD, GRL and YJQ contributed to the study design and interpretation of the results. ZP, JL, SY, XJJ, TXF, ZC, JSD, LY, YDS and LTY contributed to the collection, analysis, or interpretation of data. WPZ prepared the manuscript. YJQ, GRL, XB, YYJ, ZXY, JSD and YDS critically revised the manuscript. All authors read and approved the final submitted version.

**Acknowledgements**

We give special thanks to the staff in the Department of Cardiology and Catheterization Laboratory, Fu Wai Hospital for their research contributions.

**Conflict of interest statement**

None

**References**

1. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, Gannot S, Samuel M, Weisbrod M, Bierstone D et al: *Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry*. J Am Coll Cardiol 2012, 59(11):991-997.

2. Tomasello SD, Boukhris M, Giubilato S, Marzà F, Garbo R, Contegiacomo G, Marzocchi A, Niccoli G, Gannor A, Varbella F et al: *Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions*. Eur Heart J 2015, 36(45):3189-3198.
3. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ et al: 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019, 40(2):87-165.

4. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J et al: A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 2018, 39(26):2484-2493.

5. Choi KH, Yang JH, Song YB, Hahn JY, Choi JH, Gwon HC, Lee SH, Choi SH: Long-term clinical outcomes of patients with coronary chronic total occlusion treated with percutaneous coronary intervention versus medical therapy according to presence of diabetes mellitus. EuroIntervention 2017, 13(8):970-977.

6. Ma Y, Li D, Li J, Li Y, Bai F, Qin F, Zhou S, Liu Q: Percutaneous coronary intervention versus optimal medical therapy for patients with chronic total occlusion: a meta-analysis and systematic review. J Thorac Dis 2018, 10(5):2960-2967.

7. Park TK, Lee SH, Choi KH, Lee JM, Yang JH, Song YB, Hahn JY, Choi JH, Gwon HC, Lee SH et al: Late Survival Benefit of Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion: A 10-Year Follow-Up Study. J Am Heart Assoc 2021, 10(6):e019022.

8. Shah A: Chronic Total Occlusion Coronary Intervention: In Search of a Definitive Benefit. Methodist Debakey Cardiovasc J 2018, 14(1):50-59.

9. Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, Kang H, Kang SJ, Kim YH, Lee CW et al: Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. Circulation 2019, 139(14):1674-1683.

10. Iglesias JF, Degrauwe S, Rigamonti F, Noble S, Roffi M: Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients with Diabetes Mellitus: a Treatment-Risk Paradox. Curr Cardiol Rep 2019, 21(2):9.

11. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52(4):255-262.

12. Brilakis ES, Banerjee S, Karpaliotis D, Lombardi WL, Tsai TT, Shunk KA, Kennedy KF, Spertus JA, Holmes DR, Jr., Grantham JA: Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv 2015, 8(2):245-253.

13. Michael TT, Karpaliotis D, Brilakis ES, Fuh E, Patel VG, Mogabgab O, Alomar M, Kirkland BL, Lembo N, Kalynych A et al: Procedural outcomes of revascularization of chronic total occlusion of native coronary arteries (from a multicenter United States registry). Am J Cardiol 2013, 112(4):488-492.

14. Salisbury AC, Sapontis J, Grantham JA, Qintar M, Gosch KL, Lombardi W, Karpaliotis D, Moses J, Cohen DJ, Spertus JA et al: Outcomes of Chronic Total Occlusion Percutaneous Coronary...
Intervention in Patients With Diabetes: Insights From the OPEN CTO Registry. *JACC Cardiovasc Interv* 2017, **10**(21):2174-2181.

15. Tsai CT, Huang WC, Teng HI, Tsai YL, Lu TM: Long term clinical impact of successful recanalization of chronic total occlusion in patients with and without type 2 diabetes mellitus. *Cardiovasc Diabetol* 2020, **19**(1):119.

16. Galassi AR, Werner GS, Boukhris M, Azzalini L, Mashayekhi K, Carlino M, Avran A, Konstantinidis NV, Grancini L, Bryniarski L *et al.*: Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. *EuroIntervention* 2019, **15**(2):198-208.

17. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM *et al.*: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011, **58**(24):e44-122.

18. Association AD: **2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.** *Diabetes Care* 2019, **42**(Suppl 1):S13-s28.

19. Kuo CF, Yu KH, Shen YM, See LC: The Chinese version of the modification of diet in renal disease (MDRD) equation is a superior screening tool for chronic kidney disease among middle-aged Taiwanese than the original MDRD and Cockcroft-Gault equations. *Biomed J* 2014, **37**(6):398-405.

20. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS *et al.*: Third universal definition of myocardial infarction. *Eur Heart J* 2012, **33**(20):2551-2567.

21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P *et al.*: Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007, **115**(17):2344-2351.

22. Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC, Jr., Ge J, Ma C, Han Y, Fonarow GC *et al.*: Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. *Cardiovasc Diabetol* 2018, **17**(1):147.

23. Mashaly A, Rha SW, Choi BG, Baek MJ, Ryu YG, Choi SY, Byun JK, Li H, Shim MS, Jang WY *et al.*: Impact of diabetes mellitus on 5-year clinical outcomes in patients with chronic total occlusion lesions. *Coron Artery Dis* 2018, **29**(2):119-126.

24. Sanguineti F, Garot P, O’Connor S, Watanabe Y, Spaziano M, Lefèvre T, Hovasse T, Benamer H, Unterseeh T, Chevalier B *et al.*: Chronic total coronary occlusion treated by percutaneous coronary intervention: long-term outcome in patients with and without diabetes. *EuroIntervention* 2017, **12**(15):e1889-e1897.

25. Yan Y, Zhang M, Yuan F, Liu H, Wu D, Fan Y, Guo X, Xu F, Zhang M, Zhao Q *et al.*: Successful revascularization versus medical therapy in diabetic patients with stable right coronary artery chronic total occlusion: a retrospective cohort study. *Cardiovasc Diabetol* 2019, **18**(1):108.
26. Guo L, Wang J, Ding H, Meng S, Zhang X, Lv H, Zhong L, Wu J, Xu J, Zhou X et al: Long-term outcomes of medical therapy versus successful recanalisation for coronary chronic total occlusions in patients with and without type 2 diabetes mellitus. Cardiovasc Diabetol 2020, 19(1):100.

27. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL et al: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356(15):1503-1516.

28. Yang ZK, Shen Y, Shen WF, Pu LJ, Meng H, Zhang Q, Lu L, De Caterina R, Chen QJ: Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. Int J Cardiol 2015, 197:241-247.

29. Dai Y, Shen Y, Li QR, Ding FH, Wang XQ, Liu HJ, Yan XX, Wang LJ, Yang K, Wang HB et al: Glycated Apolipoprotein A-IV Induces Atherogenesis in Patients With CAD in Type 2 Diabetes. J Am Coll Cardiol 2017, 70(16):2006-2019.

30. Şen Ö, Allahverdiyev S, Topuz M, Baykan AO, Oz F, Koç M: Clinical significance and determinants of prompt recruitment collaterals during primary percutaneous coronary intervention. Kardiol Pol 2017, 75(8):763-769.

31. Shen Y, Ding FH, Dai Y, Wang XQ, Zhang Q, Lu L, Shen WF: Reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion. Cardiovasc Diabetol 2018, 17(1):26.

32. Shen Y, Lu L, Ding FH, Sun Z, Zhang Q, Yang ZK, Hu J, Chen QJ, Shen WF: Association of increased serum glycated albumin levels with low coronary collateralization in type 2 diabetic patients with stable angina and chronic total occlusion. Cardiovasc Diabetol 2013, 12:165.

33. Yang ZK, Shen Y, Dai Y, Wang XQ, Hu J, Ding FH, Zhang Q, Lu L, Shen WF: Impact of coronary collateralization on long-term clinical outcomes in type 2 diabetic patients after successful recanalization of chronic total occlusion. Cardiovasc Diabetol 2020, 19(1):59.

34. Zhu Y, Meng S, Chen M, Liu K, Jia R, Li H, Zhu H, Jin Z: Long-term prognosis of chronic total occlusion treated by successful percutaneous coronary intervention in patients with or without diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 2021, 20(1):29.

35. Ruiz-Garcia J, Teles R, Rumoroso JR, Cyrne Carvalho H, Goicolea FJ, Moreu J, Mauri J, Mainar V, García E, Moreno R: Comparison between diabetic and non-diabetic patients after successful percutaneous coronary intervention for chronic total occlusions in the drug-eluting stent era. Rev Port Cardiol 2015, 34(4):263-270.

36. Strain WD, Paldánius PM: Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol 2018, 17(1):57.

Figures
Figure 1

Study flow chart. CAD: coronary artery disease; PCI: percutaneous coronary intervention; CTO: chronic total occlusion; HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; STEMI: ST-segment elevation myocardial infarction.
Figure 2

Kaplan Meier survival curves for 5 years (A) all-cause mortality; (B) MACCE; (C) cardiac death; (D) MI; (E) stroke; (F) TVR in entire population. MACCE: major adverse cardiac and cerebrovascular events; MI: myocardial infarction; TVR: target-vessel revascularization.
Figure 3

Subgroup analysis on MACCE between the diabetes group and the non-diabetes group. MACCE: major adverse cardiac and cerebrovascular events; LVEF: left ventricular ejection fraction; LAD: left ascending coronary artery; NA: not applicable.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.xlsx